Search
Sumario de resultados
TIpos de contenido
Fecha
-
CompanyONENA MEDICINES
-
-
Press releaseBiotechnology revolutionizes early detection of prostate cancer, the incidence of which co...
Biotechnology is central to the diagnosis, treatment and follow-up of prostate cancer and plays a broad role across the spectrum of patient care. Telomere measurement technology represents a useful
-
NewBiotechnology and bio-manufacturing win 350 million euros in support and investment from E...
The European Commission thus reinforces biotechnology as central to Europe's green, digital and long-term industrial transition.
-
NewRafael Simó: "We should talk about "obesities" instead of "obesity" because more and more...
Geneis Biomed interviews Dr. Rafael Simón, head of the Endocrinology and Nutrition Department at Vall d'Hebron University Hospital and Director of the Diabetes and Metabolism Research Unit at Vall d
-
CompanyASPARIA GLYCOMICS
-
NewBiotechnology: key to addressing the triple environmental crisis and achieving the Sustain...
Biotechnology addresses environmental challenges through bioremediation, the production of renewable energy, sustainable agriculture, or the reduction of greenhouse gas emissions.
-
Press release
Biotechnology: key to addressing the triple environmental crisis and achieving the Sustain...
Biotechnology addresses environmental challenges through bioremediation, the production of renewable energy, sustainable agriculture, or the reduction of greenhouse gas emissions. Biofuels are one of
-
NewRegister for Webinar: Oligonucleotide Drugs: Key ADME & DMPK Insights
Pharmaron is holding a training webinar on June 20 on the importance of oligonucleotide drugs in modern medicine.
-
NewUse of biotechnology in advanced therapies and new technologies in the spanish market
Among the most important emerging technologies are the manipulation of the microbiota, CAR-T cell therapies, and gene editing using CRISPR-Cas9, techniques that are positioning Spain as a benchmark in
-
NewVIVEbiotech receives the “New Company of Gipuzkoa 2024” award from ADEGI
The award recognizes the success of companies less than 10 years old that create wealth and employment in the Basque Country community.
-
NewOryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ...
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML). The combination showed substantial
-
CompanyPARALAB
-
NewOryzon to provide corporate progress updates at several events in June
BIO International Convention 2024. Congreso de la European Hematology Association (EHA) 2024. European Network to Cure ALS (ENCALS) 2024.
-
NewBCN HEALTH publishes a study estimating the cost of thalassaemia care across the world
BCN HEALTH desarrolló un modelo de costes aplicable a nivel mundial para la atención de la talasemia.
-
NewOryzon selected as Associated Partner in the first Important Project of Common European In...
Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain . Oryzon to validate epigenetic agents by applying a personalized
-
NewCollaboration, efficient management of intellectual property and creation of spin-offs, vi...
AseBio has organized, within the framework of the XVII Annual Conference of Biomedical Research Technology Platforms (Barcelona), the debate entitled “Collaboration and transfer: the DNA of biomedical
-
Press release
Collaboration, efficient management of intellectual property and creation of spin-offs, vi...
AseBio has organized, within the framework of the XVII Annual Conference of Biomedical Research Technology Platforms (Barcelona), the debate entitled “Collaboration and transfer: the DNA of biomedical
-
NewFour AseBio partners will participate in the first IPCEI in the health sector that will mo...
The Major Project of Common European Interest 'Med4Cure' will enable member states to support a total of 14 projects from 13 companies that will result in more than 70 collaborations, as well as 11
-
NewKey Considerations for Cell and Gene Therapy Commercialization in Non-Orphan Indications
There are two important challenges for companies aiming to develop CGTs in mainstream indications.
-
NewAircure®Tech, a technology that will change the way we correct excess CO2
Since 2023, the company has been certified as an Innovative SME.